C4 Therapeutics Inc
CCCC
Get informed when a big investor buys or sells
+ FollowMarket Cap$326.17M
Close$
$-3.08
204.3% downside
Current Fair Value
204.3% downsideOvervalued by 204.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $326.17 Million |
|---|---|
| Enterprise Value | $331.08 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.27 |
| Beta | 2.95 |
| Outstanding Shares | 130,696,742 |
Return
| Return on Equity | -41.02% |
|---|---|
| Return on Assets | -28.22% |
| Return on Invested Capital | -34.13% |
Valuation & Multiples
| P/E Ratio | -2.95 |
|---|---|
| PEG | 32.18 |
| Price to Sales | -2.95 |
| Price to Book Ratio | 2.95 |
| Enterprise Value to Revenue | -27.28 |
| Enterprise Value to EBIT | -3.12 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 0.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$7.67 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$8.82 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1211▼ 7.44% |
|---|---|
| Total Calls | 911,300▲ 281.62% |
| Total Puts | 110,400▲ 136.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 93.98%▲ 26.96% |
|---|---|
| Total Invested | $551.41M▲ 149.17% |
| Investors Holding | 158▲ 30.00% |
ESG Score
No data
About C4 Therapeutics Inc
99 employeesC4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and o...